source
- Argenx CEO Karen Massey drives $3.4 billion of acquisitions to expand beyond VyvgartArgenx, a rare‑disease biotech, announced that under its new CEO Karen Massey it has pursued two acquisitions. The deals together have a potential value of about $3.4 billion and are intended to b…
- HHS commits up to $25M for ibogaine and other psychotropic drugs on Veteran's DayHHS announced an investment of up to $25 million for ibogaine and other rapid acting psychotropic medicines aimed at serious mental illnesses such as PTSD, unveiled on Veteran's Day. Up to $4.9 mi…